Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Week 1: dose finding; week 2-5: stable dose, max. 10 sprays * Part A: first week average number of sprays: 3.6, second week: 6.4 * Part B: average daily number: 6.3)

• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Sativex® (nabiximol, THC 27 mg/mL, CBD 25 … Sativex® (nabiximol, THC 27 mg/mL, CBD 25 mg/mL) via oral spray (self-applied by patient);</br>week 1: dose finding; week 2-5: stable dose, max. 10 sprays</br></br>* Part A: first week average number of sprays: 3.6; second week: 6.4</br>* Part B: average daily number: 6.5k: 6.4 * Part B: average daily number: 6.5)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  +